Breaking News Bar

Business News and Information

PhaseBio completes $49.5M stock sale

The Malvern company focused on orphan diseases plans to use the $39 million in net proceeds to advance its two lead new drug candidates.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear